Endo Y, Shimazu M, Sakuragawa T, Uchi Y, Edanami M, Sunamura K, Ozawa S, Chiba N, Kawachi S. Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report. World J Gastrointest Surg 2022; 14(3): 260-267 [PMID: 35432767 DOI: 10.4240/wjgs.v14.i3.260]
Corresponding Author of This Article
Motohide Shimazu, MD, PhD, Chief Doctor, Department of Surgery, Tama Kyuryo Hospital, 1491 Shimo-oyamadacho, Machida, Tokyo 1940297, Japan. shimazu@tokyo-med.ac.jp
Research Domain of This Article
Surgery
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yutaka Endo, Motohide Shimazu, Tadayuki Sakuragawa, Yusuke Uchi, Motonori Edanami, Ken Sunamura, Soji Ozawa, Department of Surgery, Tama Kyuryo Hospital, Tokyo 1940297, Japan
Naokazu Chiba, Shigeyuki Kawachi, Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo 1930998, Japan
Author contributions: Endo Y participated in the patient care, conceptualization, data curation, visualization and wrote the original article; Shimazu M participated in the patient care, reviewed the article, and supervised this report; Ozawa S, Kawachi S, Chiba N, Sakuragawa T, Uchi Y, Sunamura K reviewed the article; Edanami M participated in the patient care.
Informed consent statement: Written informed consent was obtained from this patient.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Motohide Shimazu, MD, PhD, Chief Doctor, Department of Surgery, Tama Kyuryo Hospital, 1491 Shimo-oyamadacho, Machida, Tokyo 1940297, Japan. shimazu@tokyo-med.ac.jp
Received: November 30, 2021 Peer-review started: November 30, 2021 First decision: December 26, 2021 Revised: January 8, 2022 Accepted: March 16, 2022 Article in press: March 16, 2022 Published online: March 27, 2022 Processing time: 115 Days and 13.8 Hours
Core Tip
Core Tip: A 63-year-old woman had chronic hepatitis B virus infection and previous treatment history of hepatocellular carcinoma. She developed a 43-mm splenic mass and tumor thrombus involving the right portal branch and an umbilical portion extending down to the main trunk with severe ascites. She was initially treated with regorafenib and then lenvatinib. Ten months post-treatment, there was no contrast enhancement of portal vein tumor thrombosis or splenic metastases. However, after lenvatinib discontinuation due to severe diarrhea, splenic metastases showed partial contrast enhancement. Subsequently, hand-assisted laparoscopic splenectomy was performed with no remarkable postoperative complications. She experienced no recurrence for 14 mo.
